Takeda Partner Santhera Commences Phase III Trial For Duchenne Muscular Dystrophy Drug
This article was originally published in PharmAsia News
Executive SummaryJapan's Takeda disclosed recently that Swiss partner Santhera has commenced a pivotal Phase III trial for Catena/Sovrima (idebenone), which could be the first drug to treat Duchenne Muscular Dystrophy, a rare disease that affects an estimated 30,000 European and North American male patients mainly in their teens
You may also be interested in...
A full pipeline of symptomatic and disease-modifying treatments for Duchenne will transform a long dormant orphan market into a hotly contested commercial prize. But some issues, foremost the scarcity of trial patients, threaten to stall progress in the field.
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).